Member Info for Onassis

Share Priice being played. Watch it pick up before COP today.

This is your investment... work for it, protect it and don't panic on the words of very shadowy figure that "has your best interest in their heart". Consider that one factor: Someone you have never met, is not a member of your family, is now, out of the goodness of their hearts - GIVING YOU FREE ADVICE (that you didn't ask for). It's a no brainer. They have motive - THEY WANT YOUR SHARES

This will pick up, to many buy incoming.

Simply oversold, great opportunity to buy

Just a little reminder:

Avacta Group has struck an exclusive distribution agreement with a new company established by a pair of Boohoo founder shareholders for direct-to-consumer sales of a saliva-based rapid test for the Covid-19 antigen. The development is considered to be a "major step forward" in the fight against the disease.

The listed company, which has sites in Wetherby and Cambridge, has partnered with Cytiva – formerly GE Healthcare Life Sciences – to develop a product designed to give a result within minutes for use by both healthcare professionals and consumers.

It has now agreed an exclusive distribution agreement with Medusa19, which has been established by Richard Hughes and Mahmud Kamani.

Medusa's initial focus will be on Covid-19 home testing. It is currently investing in global e-commerce, logistics and customer support infrastructure in preparation for Avacta's test launch.

The company will also have non-exclusive rights to supply the tests to businesses for workforce testing, with the distribution agreement including a profit-sharing arrangement.

Hughes and Kamani said: "We immediately recognised the global opportunity to distribute the simple and unique saliva-based Covid-19 rapid test being developed by Avacta based on their unique and powerful Affimer platform.

"Medusa19 will enable end-to-end supply of these tests on a global basis, subject to regulatory approval and manufacturing capacity, which will be key. "The enormous, world-wide demand for these tests requires a robust and scalable platform, which we are in the process of creating. Hundreds of millions are required and this demand will continue."

Dr Alastair Smith, chief executive of Avacta Group, added: "The potential size of this market, and the expected demand from businesses for workforce screening, is substantial.

"The significant investment that Medusa19 is making in conjunction with the track records of the Medusa19 team gives me great confidence in the rapid growth of direct-to-consumer sales of the Avacta COVID-19 test across the United Kingdom, European Union and the United States subject to the necessary regulatory approvals.

"I expect the commercial impact of this partnership to be very significant to Avacta."

If you didn't top up, you should have.

MMs are loaning out shares, giving a false impression. Great time to top up or buy into Avacta.

Twitter Tom Winnitfringe and gang have allegedly decided to take this down !
What the f* "#. How do these people get away with it !!

Look at all them buys... Leaky leaky

With the covid-19 numbers rocketing in the USA the quicker Avacta gets their affimer to market the better. https://www.cambridgeindependent.co.uk/business/avacta-confirms-affimer-reagents-prevent-infection-of-human-cells-in-model-of-covid-19-virus-9113916/

Will the covid-19 numbers rocketing in the USA the quicker Avacta gets their affimer to market the better. https://www.cambridgeindependent.co.uk/business/avacta-confirms-affimer-reagents-prevent-infection-of-human-cells-in-model-of-covid-19-virus-9113916/

What is going on, not a good avert for NCYT. Could be reason for selling ....

It would be nice to be able to say otherwise, but the UK’s approach to testing in this covid-19 pandemic continues to be chaotic, centralised, commercialised, and driven by numerical targets rather than clear strategy. Allan Wilson, president of the Institute of Biomedical Sciences, has called this reactive and random approach the “wild west of testing.” Writing for BMJ Opinion this week, Chris Ham agrees. The system is far from “world beating,” and ministers must be prepared to acknowledge and learn from mistakes, he says.

What makes matters worse is the ongoing lack of honesty. The government has exaggerated the performance of its much vaunted test, track, and trace system: most contacts were traced by local health teams, with only a minority by the national, privately contracted call centres. Some reasons for this are grimly outlined by one doctor who signed up to work in them.

As for antibody testing, there are the same mistakes. Heralded by our political leaders as “game changing” and an “important milestone,” antibody testing is being ramped up, with healthcare trusts being asked to be ready to rapidly process thousands of tests a day. But a group of public health and clinical experts warn that this makes no sense: these tests are NOT useful in diagnosis and can’t be relied on.

COYS1882 ?

Are we going tick up ?into close as usual!!

We know big big news is on the way .. Won't be long now.

Posted on ADVFN

Below BBC news relates to ANTI-BODY TEST - Doesn't concern Avacta Group.
https://www.bbc.co.uk/news/health-53169618

Antibody v Antigen testing.

For newcomers unfamiliar with what Avacta are doing, it is important to know they are focussed on ANTI- GEN testing which is different from ANTI- BODY testing.

To be 100% clear:
ANTI-GEN Tests if you currently HAVE the virus.
ANTI-BODY - Tests if you HAD the virus.

Avacta Group confirms affimer reagents block the COVID-19 virus

Wow......Game On

https://www.***************************/avacta-group-rapid-antigen-test-and-affimer-reagents-that-block-the-covid-19-virus-interview/412836284

142.3 paid

Couple of nice buys just come in